Elan commences planned measures to reduce indebtedness

NewsGuard 100/100 Score

Elan Corporation, plc ("Elan") (NYSE: ELN) announced today that it has commenced planned measures to reduce its indebtedness using the cash proceeds received in connection with the combination of its EDT business with Alkermes Inc., which closed today.

Asset Sale Offer. Elan's wholly-owned subsidiaries, Elan Finance public limited company ("Elan Finance") and Elan Finance Corp. ("Elan Corp" and together with Elan Finance, the "Issuers"), commenced an offer to purchase (the "Asset Sale Offer") up to $721.2 million in aggregate principal amount of their senior notes consisting of (i) 8.875% Senior Fixed Rate Notes due 2013 (the "2013 Fixed Rate Notes"), (ii) Senior Floating Rate Notes Due 2013 (the "2013 Floating Rate Notes" and, together with the 2013 Fixed Rate Notes, the "2013 Notes"), (iii) 8.750% Senior Notes due 2016 issued on October 2, 2009 (the "2016 Senior Notes issued October 2009") and (iv) 8.750% Senior Notes due 2016 issued on August 17, 2010 (the "2016 Senior Notes issued August 2010" and, collectively with the 2013 Notes and the 2016 Senior Notes issued October 2009, the "Notes"), in accordance with the terms of the indentures governing the Notes (the "Indentures"), at a purchase price of 100% of the principal amount thereof, plus accrued and unpaid interest thereon to, but not including, the Asset Sale Offer Payment Date (as defined below). The Asset Sale Offer will expire at 11:59 p.m., New York City time, on October 14, 2011 (the "Asset Sale Expiration Date"), unless extended. Validly tendered Notes may be withdrawn at any time prior to 11:59 p.m., New York City time, on the Asset Sale Offer Expiration Date. Settlement for the Asset Sale Offer is expected to occur on October 17, 2011 (the "Asset Sale Offer Payment Date").

The Asset Sale Offer is being made as a result of Elan's sale of its EDT business to an unrestricted subsidiary of Elan prior to the combination of the EDT business with Alkermes, Inc. That sale constituted an "asset sale" under the Indentures and the source of funds for the Asset Sale Offer is the cash proceeds received by Elan in connection with that sale.

The Asset Sale Offer is being made pursuant to an Offer to Purchase, dated September 16, 2011, and related documents (collectively, the "Asset Sale Offer Documents"), which set forth the complete terms and conditions of the Asset Sale Offer. The Asset Sale Offer is made only by and pursuant to the terms set forth in the Asset Sale Offer Documents, and the information in this press release is qualified by reference to those documents. Subject to applicable law, the Issuers may amend, extend or terminate the Asset Sale Offer.

Tender Offer. Elan also announced today that the Issuers are commencing a cash tender offer (the "Tender Offer") for the 2013 Fixed Rate Notes. The maximum amount of 2013 Fixed Rate Notes that will be purchased in the tender offer will not exceed the Maximum Tender Cap (as defined below). The "Maximum Tender Cap" means $721.2 million minus the sum of (i) the aggregate principal amount of all Notes accepted for purchase in the Asset Sale Offer plus (ii) the aggregate principal amount of 2013 Floating Rate Notes to be redeemed by the Issuers pursuant to the Redemption (as defined below). The Tender Offer is being made pursuant to an Offer to Purchase, dated September 16, 2011, and related documents (collectively, the "Tender Documents"), which set forth the complete terms and conditions of the Tender Offer. The Tender Offer is made only by and pursuant to the terms set forth in the Tender Documents, and the information in this press release is qualified by reference to those documents. Subject to applicable law, the Issuers may amend, extend or terminate the Tender Offer.

The total consideration for the Tender Offer is $1,032.39 per $1,000 principal amount of 2013 Fixed Rate Notes, plus accrued and unpaid interest to, but not including, the Tender Offer Payment Date (as defined below). The expiration date for the Tender Offer is 11:59 p.m., New York City time, on October 14, 2011, unless extended (the "Tender Offer Expiration Date"). Validly tendered 2013 Fixed Rate Notes may be withdrawn at any time prior to 11:59 p.m., New York City time, on the Tender Offer Expiration Date. Settlement for the Tender Offer is to occur on a date (the "Tender Offer Payment Date") promptly following the Tender Expiration Date, subject to the satisfaction or waiver of certain conditions set forth in the Tender Documents, including the consummation of the Asset Sale Offer. We currently anticipate that the Tender Offer Payment Date will occur on October 17, 2011.

Elan has retained Morgan Stanley & Co. LLC to act as the Dealer Manager in connection with the Tender Offer. Any holder that has questions concerning the terms of the Tender Offer may contact Morgan Stanley at +1 (800) 624-1808 (toll free) or +1 (212) 761-1057 (collect).

Tender Documents will only be distributed to holders of the 2013 Fixed Rate Notes. Holders who desire a copy of the Tender Documents should contact D.F. King & Co., Inc., the information agent and depositary for the Tender Offer, at +1 (800) 431-9645 or +1 (212) 269-5550.

Redemption. Elan also announced today that the Issuers have elected to redeem all of the 2013 Floating Rate Notes, of which $10,530,000 in aggregate principal amount is currently outstanding (the "Redemption"). The 2013 Floating Rate Notes are redeemable at the option of the Issuers at a redemption price of 100% of the principal amount thereof, plus accrued but unpaid interest thereon to, but not including, the redemption date, which will be October 17, 2011. A notice of redemption, containing the applicable redemption procedures, has been distributed to the holders of the 2013 Floating Rate Notes.

Source:

Elan Corporation, plc

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.